Progress of immune checkpoint inhibitors in aggressive pituitary adenomas / 中华内分泌代谢杂志

ABSTRACT

Pituitary adenomas(PAs) are the most common types of central nervous system tumors. Although most of them are benign tumors, aggressive PAs are resistant to conventional treatments and thus increase morbidity and mortality. Immunotherapy is a promising treatment and has been applied in treatment of kinds of neoplasms, including aggressive PAs. This review summarizes recent advances of immune checkpoint inhibitors in PAs.